2026

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis
Al-Bazaz M, Alsdorf W, Leypoldt L, Sonnemann P, Schaefers C, Artzenroth J, Harzer M, Kamili A, Bartke L, Cords L, Vorwerk J, Leitner T, Maulhardt M, Brinkert K, Brioli A, Richardson T, Holtick U, Hillmann S, Salwender H, Khandanpour C, Bokemeyer C, Weisel K, Kosch R
AM J HEMATOL. 2026;101(7):1433-1439.

Hepatitis E virus infections in people with multiple myeloma an emerging challenge in the era of immunotherapeutic approaches
Al-Bazaz M, Pischke S, Alsdorf W, Sonnemann P, Cichutek S, Wiesch J, Schaefers C, Artzenroth J, Leypoldt L, Kamili A, Bokemeyer C, Weisel K, Kosch R
HAEMATOLOGICA. 2026;111(3):1017-1028.

Malignancy-Associated Hemophagocytic Lymphohistiocytosis: Clinical Characteristics, Treatment Patterns, and Survival Outcomes in a Tertiary Care Center Cohort
Kosch R, Alsdorf W, Ahmadi P, Hölzemer A, Abdelrahim A, Ahrens K, Bokemeyer C, Weisel K, Sonnemann P, Al-Bazaz M
CL LYMPH MYELOM LEUK. 2026 [Epub ahead of print].

2025

Respiratory syncytial virus infection in patients with haematological diseases: a retrospective multicentre study
Herrmann S, Graefe S, Christopeit M, Sonnemann P, Hattenhauer T, Mispelbaum R, Monin M, Orth H, Glasshove C, Gruell H, Klein F, Klein U, Lehmann C, Naendrup J, Stemler J, Salmanton-Garcia J, Markus T, Cornely O, Mellinghoff S
INFECTION. 2025;53(4):1341-1350.

2024

Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML)
Schönrock M, Sonnemann P, Michalowski N, Heuser M, Thol F, Ayuk F, Wolschke C, Klyuchnikov E, Bokemeyer C, Fiedler W, Cichutek S
CANCERS. 2024;16(22):.

2020

Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients
Ghandili S, Pfefferle S, Roedl K, Sonnemann P, Karagiannis P, Boenisch O, Kluge S, Schmiedel S, Ittrich H, Rohde H, Lütgehetmann M, Weisel K, Bokemeyer C, Wichmann D, Fiedler W, Jarczak D, Modemann F
BLOOD ADV. 2020;4(23):5936-5941.

Letzte Aktualisierung aus dem FIS: 23.07.2026 - 00:39 Uhr